Showing 1481-1490 of 10035 results for "".
ILUMYA SUPPORT™ patient access for commercial and Medicare Part B patients
https://practicaldermatology.com/topics/psoriasis/ilumya-support-patient-access-for-commercial-and-medicare-part-b-patients/19860/ILUMYA SUPPORT™ offers comprehensive programs and services to help patients start and stay on therapy with ILUMYA™. Learn about the three main patient access programs offered by ILUMYA SUPPORT™: the Early Access Program, the Co-pay Program, and the Patient Assistance Program. ILUMYA™ is reimbursed uHow Do You Treat Alopecia Areata of the Eyebrows?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/how-do-you-treat-alopecia-areata-of-the-eyebrows/19822/Intralesional corticosteroids are a key part of treatment. Dr. Friedman discusses safe use, as well as additional treatment strategies.FDA Approvals, Acne Insights, EPI Gets Cloderm
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approvals-acne-insights-epi-gets-cloderm/18230/In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US mayMeeting Recap: Aesthetic Extenders Symposium 2018
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/meeting-recap-aesthetic-extenders-symposium-2018/18234/Faculty and industry partners discuss the highlights of the Aesthetic Extenders Symposium. From novel uses of toxins to skincare and injections techniques, AES provided a range of updates. AES 2019 will be held in Miami, FL.Altreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobAllergan's Cool Campaign, Obagi Line Launches, Apple Upgrades Health App
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-s-cool-campaign-obagi-line-launches-apple-upgrades-health-app/18346/There's some misleading information about fat reduction out there, and that's not cool, Allergan says. The company's CoolSculpting device has launched the “Not Cool Vs. Cool” campaign. Data show patients and doctors assess scars differently: Patients tend to focus on scar depth, while physicians focTwo Launches from Cutera, AmSpa Projections
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-two-launches-from-cutera-amspa-projections/18356/Cutera introduces two new devices to its laser and energy-based device offerings: Juliet laser represents Cutera's first entry into the women's health segment of the aesthetics market; Secret RF is a new fractional radio frequency microneedling device that effectively remodels collagen, improves milJanssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeSummer AAD Highlights, Alopecia Areata Discovery
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-summer-aad-highlights-alopecia-areata-discovery/18846/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, new research that suggests emerging biologic therapies could help treat alopecia areata. Plus, updates on atopic dermatitis and eczema, hands-on education, and Kybella from the AAD Summer meeting. AndEpiduo Forte Approved; Facial Aesthetics By Age
https://practicaldermatology.com/topics/practice-management/dermwiretv-epiduo-forte-approved-facial-aesthetics-by-age/18870/Galderma's non-antibiotic Epiduo Forte (Adapalene 0.3% and benzoyl peroxide 2.5%) approved for topical management of acne vulgaris. Trends reveal differences in women's facial cosmetic surgery by age. AMA and CMS offer ICD-10 help. Plus: An Update on NewDerm LIVE.